EWA
ENTA icon

Evolution Wealth Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Evolution Wealth Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-126
Closed -$8K – 642
2019
Q3 		$8K Sell
126
-32
-20% -$2.38K ﹤0.01% 209
2019
Q2 		$13K Buy
+158
New +$14.2K 0.01% 158

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Evolution Wealth Advisors's ENTA Position: Q4 2019 in Review

Evolution Wealth Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q4 2019, closing a stake of 126 shares — an estimated $8K sold.

Evolution Wealth Advisors first reported a position in ENTA in Q2 2019 and held it in 2 quarters. The position peaked at $13K in Q2 2019. 171 funds tracked by Wall St. Rank hold ENTA as of Q4 2019.

  • Evolution Wealth Advisors reported no remaining Enanta Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Evolution Wealth Advisors sold 126 Enanta Pharmaceuticals shares in Q4 2019, an estimated $8K.
  • Evolution Wealth Advisors first reported a position in Enanta Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Evolution Wealth Advisors's Enanta Pharmaceuticals position peaked at $13K in Q2 2019.
  • 171 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2019.

Based on Evolution Wealth Advisors's 13F filing for Q4 2019, filed 3 Feb 2020.